JPRN-UMIN000050067
Recruiting
Phase 2
A Phase II study of the efficacy and safety of Perflubutane for predicting highly Tumor Infiltrating Lymphocytes in early breast cancer (AppTIL study) - A Phase II study of the Perflubutane for predicting TILs in EBC (AppTIL study)
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hiroshima University Hospital
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients undergoing preoperative treatment for breast cancer 2\. Patients with a history of breast cancer on the affected side 3\. Patients with a history of hypersensitivity to perflubutane 4\. Patients with allergy to eggs or egg products 5\. Patients with arteriovenous shunts in the heart or lungs 6\. Patients with serious cardiac or pulmonary disease 7\. Patients deemed inappropriate by the principal investigator or subinvestigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A Phase II study of the Perflubutane for predicting TILs in EBC (AppTIL study)Early Breast Cancer (cStage I-IIIA)Breast Cancer, TIL, Tumor Infiltrating Lymphocyte, LPBC, Contrast-enhanced ultrasonography, US, Perflubutane, SonazoidJPRN-jRCT1061220081Shigematsu Hideo100
Completed
Not Applicable
Phase II study evaluating efficacy and safety of peripheral blood stem cell harvest with bortezomib for multiple myelomaJPRN-UMIN000010258Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine30
Completed
Not Applicable
Clinical trial for effectiveness and safety of percutaneous transhepatic gallbladder aspiration in patients with acute cholecystitisAcute cholecystitisJPRN-UMIN000002052Chiba University Graduate School of Medicine78
Recruiting
Phase 1
Clinical and translational controlled study of Perampanel treatment around Surgery in patients with progressive glioblastoma (PerSurge)Progressive GlioblastomaMedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2023-503938-52-00niversitaetsklinikum Heidelberg AöR66
Completed
Phase 2
Phase II analysis for efficacy and safety of perioperative pirfenidone (Pirespa) therapy for patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis (IPF)non-small-cell lung cancer combined with idiopathic pulmonary fibrosisJPRN-UMIN000007774West Japan Oncology Group42